Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Duke Scientists Identify New Way To Block Blood Vessels That Feed Cancer Growth

21.05.2004


Scientists from Duke University Medical Center have identified the "master switch" that cancer cells use to dispatch protective messages to nearby blood vessels, fortifying the vessels against deadly onslaughts of radiation.



The messages enable blood vessels to survive and ultimately nourish any remaining cancer cells that escape toxic radiation therapy.

Radiation biologists from the Duke Comprehensive Cancer Center identified the master switch as a protein called "Hypoxia Inducible Factor" (HIF-1) that turns on production of these protective messages.


They suppressed HIF-1 with experimental drugs given together with radiation therapy in animals with cancer. In doing so, they successfully inhibited blood vessel growth in tumors and, thereby, the growth of tumors themselves.

The Duke scientists hope to test this potential new therapy plus radiation in humans within the very near future. Results of their current findings are reported in the May, 2004, issue of Cancer Cell.

"HIF-1 is the switch inside cancer cells that gets turned on by radiation therapy," said Mark Dewhirst, Ph.D., DVM, professor of radiation oncology at Duke and principal investigator of the study. "Once it is activated, HIF-1 then triggers the production of well-known growth factors such as VEGF and bFGF, as well as more than forty different protein signals that regulate tumor metabolism, metastasis and angiogenesis." Angiogenesis is the process by which cancer cells grow new blood vessels to nourish and sustain themselves.

"By blocking the master switch, we effectively blocked many of the proteins which promote angiogenesis," said Dewhirst.

The Duke discovery follows dozens of recent developments in the field of anti-angiogenesis, in which scientists have attempted to block specific proteins that give rise to or protect tumor-feeding blood vessels.

The most noteworthy success has been Avastin, the first drug to be approved by the FDA to suppress angiogenesis in patients with spreading colorectal cancer. Avastin inhibits the protein VEGF and has been shown to extend patients’ lives when taken together with chemotherapy.

Dewhirst and first author Benjamin Moeller said their technique of suppressing HIF-1 expression could, theoretically, be a more potent inhibitor of blood vessel survival than the current approach of just suppressing a single protein, such as VEGF.

"We’re employing a treatment strategy where we accomplish two hits -- killing the cancer cells with radiation and blocking their blood vessel survival with an anti-HIF drug," said Moeller, a graduate student in the Duke M.D./Ph.D. program. "By pinpointing and blocking the source of all the signals, we have successfully halted the cancerous blood vessel growth in animals without harming normal blood vessels."

Approximately half of all cancer patients in the U.S. are treated with radiation therapy. However, the success of therapy depends largely on how sensitive a tumor’s blood vessels are to radiation. If blood vessels in the tumor survive after radiation, they can provide nutrients to the surviving cancer cells to begin rebuilding the tumor.

Thus, knowing how HIF-1 works inside cancer cells is critical to manipulating its behavior and making its blood vessels more responsive to radiation, said Moeller.

It is already known that radiation boosts oxygen levels inside cancer cells. In the new study, Moeller demonstrated that the infusion of oxygen releases pent-up RNA, the genetic blueprint molecule, for HIF-1 protein which is bound up in tiny particles called stress granules. The oxygen disintegrates these stress granules and allows HIF-1 to be produced and to engage in production of growth factors.

Secondarily, the infusion of oxygen produces "reactive oxygen species" -- also known as oxygen free radicals -- inside cancer cells. Reactive oxygen species were also shown to boost HIF-1 production, the study showed.

"Tumors so desperately seek to protect themselves against radiation that they have two completely different mechanisms for boosting HIF-1 regulated gene production to protect their blood vessels," said Dewhirst. The team’s unexpected findings shift the accepted paradigm of how HIF-1 works inside cancer cells and provides major insight into how HIF-1 regulates angiogenesis after radiation therapy, he said.

"We’ve known that oxygen levels and blood vessel growth inside tumors are two major influences on how a tumor responds to radiation and chemotherapy," said Dewhirst. "Now we’ve shown for the first time that HIF-1 is a major target we could block in combination with radiation therapy or any other therapies that causes oxygen levels to rise after treatment."

Becky Levine | dukemed news
Further information:
http://dukemednews.org/news/article.php?id=7618

More articles from Health and Medicine:

nachricht NTU scientists build new ultrasound device using 3-D printing technology
07.12.2016 | Nanyang Technological University

nachricht How to turn white fat brown
07.12.2016 | University of Pennsylvania School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

NTU scientists build new ultrasound device using 3-D printing technology

07.12.2016 | Health and Medicine

The balancing act: An enzyme that links endocytosis to membrane recycling

07.12.2016 | Life Sciences

How to turn white fat brown

07.12.2016 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>